Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.37 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18754923 | 0.83 | ALDH1A1 (0.41) | CYP3A4TSHREGLN2BDKRB2KDM4E | |
| SCHEMBL16023008 | 0.77 | MAPT (0.35) | EGLN2BDKRB2MAPTADRA1DADRA1A | |
| SCHEMBL16022680 | 0.77 | HSD11B1 (0.37) | HSD11B1EGLN2BDKRB2MAPTALDH1A1 | |
| SCHEMBL16014635 | 0.76 | BDKRB2 (0.34) | HSD11B1BDKRB2MAPTCRHR1 | |
| SCHEMBL18653357 | 0.75 | MAOB (0.36) | HSD11B1EGLN2BDKRB2CRHR1KMT2A | |
| SCHEMBL16014880 | 0.75 | HSD17B10 (0.46) | HSD11B1TSHRMAPTALDH1A1NPC1 | |
| SCHEMBL16014770 | 0.74 | SMN1; SMN2 (0.47) | CYP3A4HSD11B2HSD11B1TSHRKDM4E | |
| SCHEMBL16014783 | 0.74 | HSD11B1 (0.35) | HSD11B1EGLN2BDKRB2 | |
| SCHEMBL16014686 | 0.72 | JAK2 (0.52) | MAPTGAAMEN1KMT2A | |
| SCHEMBL8994827 | 0.72 | BDKRB2 (0.43) | BDKRB2GAAADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2964633-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| WO-2014135471-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP3A4 189/4885HSD11B2 2390/4885HSD11B1 1351/4885 |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP3A4 189/4885HSD11B2 2390/4885HSD11B1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.